Hong Kong Island, Hong Kong, China The company was established in Asia in Hong Kong. The leading representative office of defined VC is situated in the Wan Chai.
Opposing the other organizations, this ORI Capital works on 15 percentage points less the average amount of lead investments. The fund is constantly included in 2-6 deals per year. Considering the real fund results, this VC is 66 percentage points more often commits exit comparing to other organizations. The usual things for fund are deals in the range of 10 - 50 millions dollars. The increased amount of exits for fund were in 2018. The top activity for fund was in 2017. Despite it in 2019 the fund had an activity.
The current fund was established by Simone Song. We also calculated 2 valuable employees in our database.
Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline Orchard Therapeutics, Surefire Medical, Enable Injections The fund has specific favorite in a number of founders of portfolio startups. When startup sums 3 or 5+ of the founder, the probability for it to get the investment is little. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. We can highlight the next thriving fund investment areas, such as Therapeutics, Medical Device.
The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the ORI Capital, startups are often financed by Partisan Management Group, High Country Venture, Wellcome Trust. The meaningful sponsors for the fund in investment in the same round are Partisan Management Group, Temasek Holdings, Ohio Innovation Fund. In the next rounds fund is usually obtained by Venrock, Temasek Holdings, Sphera Global Healthcare Fund.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Aurum Ventures MKI | Israel, Ramat Gan, Tel Aviv |
| E&A Venture Capital | - |
| Entrenext Ventures | Florida, United States, Winter Park |
| Hard Yaka | Crystal Bay, Nevada, United States |
| HAT Sicaf SpA | Italy, Lombardia, Milano |
| Innovation Bridge | Boston, Massachusetts, United States |
| Magnum Capital | Community of Madrid, Madrid, Spain |
| New York University | New York, New York, United States |
| RF Capital | China, Shanghai |
| Rhode Island Science & Technology Advisory Council | - |
| Shri Investments | - |
| Sundiro Holding | China, Hainan, Hainan Province |
| Tempus | Chicago, Illinois, United States |
| Vodia Ventures | Boston, Massachusetts, United States |
| Wuhu Qichen Investment Management | Anhui, China, Wuhu |
| Xude Rendao | China, Shanghai |
| Yamagin Capital | Japan, Yamagata, Yamagata Prefecture |
| Yinji Chuangtou | China, Jiangsu, Suzhou |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
AffyImmune Therapeutics | $20M | 07 Oct 2021 | Newton, Massachusetts, United States | ||
| $29M | 12 May 2020 | Massachusetts, United States | |||
CG Oncology | $22M | 18 Mar 2019 | Irvine, California, United States | ||
Enable Injections | $50M | 25 Oct 2018 | Cincinnati, Ohio, United States | ||
Orchard Therapeutics | $110M | 20 Dec 2017 | London, England, United Kingdom | ||
Semma Therapeutics | $114M | 29 Nov 2017 | Cambridge, Massachusetts, United States | ||
Arterys | $30M | 15 Nov 2017 | San Francisco, California, United States | ||
Kymab | $100M | 24 Nov 2016 | England | ||
Enable Injections | $30M | 05 Oct 2016 | Cincinnati, Ohio, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
AffyImmune Therapeutics | $20M | 07 Oct 2021 | Newton, Massachusetts, United States | ||
| $29M | 12 May 2020 | Massachusetts, United States | |||
CG Oncology | $22M | 18 Mar 2019 | Irvine, California, United States | ||
Enable Injections | $50M | 25 Oct 2018 | Cincinnati, Ohio, United States | ||
Orchard Therapeutics | $110M | 20 Dec 2017 | London, England, United Kingdom | ||
Semma Therapeutics | $114M | 29 Nov 2017 | Cambridge, Massachusetts, United States | ||
Arterys | $30M | 15 Nov 2017 | San Francisco, California, United States | ||
Kymab | $100M | 24 Nov 2016 | England | ||
Enable Injections | $30M | 05 Oct 2016 | Cincinnati, Ohio, United States |
